Overview

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing InnoCare Pharma Tech Co., Ltd.